Durability of Response to SARS-CoV-2 BNT162b2 Vaccination in Patients on Active Anticancer Treatment.
prospective_cohort · Level II
Where this comes from
- Record sourced from PubMed, PMID 34379092.
- Also identified by DOI 10.1001/jamaoncol.2021.4390 and PMC identifier 8358809.
- Licence recorded as CC BY.
- The licence permits redistribution, so the abstract is shown in full and the full text is available from the publisher.
Abstract
This cohort study examines the durability of immune response from BNT162b2 vaccination for severe acute respiratory syndrome coronavirus 2 in patients with cancer vs healthy controls.
Medical subject headings
- COVID-19
- SARS-CoV-2